ArticleBiomarker research2026
Evaluating global clinical trials and development trends of antibody-drug conjugates.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Antibody-drug conjugates (ADCs) represent a breakthrough in tumor-targeted therapy, showing promise in both solid tumors and hematological malignancies. By 1 September 2025, more than 370 ADC candidates had entered clinical development, 17 unique products had received at least one regulatory approval worldwide, and more than 150 candidates had been discontinued. This study analyzes 3,077 ADC trials from Citeline Trialtrove, revealing that most trials are concentrated in the United States and China. At the data cutoff, 35% of trials were ongoing and 12% were classified as terminated in Trialtrove. ADC trials primarily focused on solid tumors, with brentuximab vedotin, disitamab vedotin, and gemtuzumab ozogamicin being the most frequently investigated agents. Early-phase trials predominated, whereas Phase III and IV trials were less frequent. EGFR, BRCA1, and TP53 were frequently recorded across trial-design and outcome-related fields. Future research should focus on advancing later-phase trials, refining safety and efficacy, and exploring new therapeutic targets with continued biomarker integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.